| Name | Title | Contact Details |
|---|
The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and com...
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.
BioLabs is the premier co-working space for life science startups.